The Emerging World of JAK Inhibitors
DOI:
https://doi.org/10.3126/njdvl.v22i2.68527Keywords:
Alopecia areata, Atopic Dermatitis, JAK inhibitors, Lichen Planus, Pruritus, Psoriasis, VitiligoAbstract
The Janus Kinase inhibitors are a new emerging class of small molecules. These target the Janus Kinase proteins located on the cell membrane. Janus Kinase proteins regulate the cellular transcription of several proteins and act as mediators in several cytokine pathways. Dysregulation in these cytokine pathways is responsible for disorders like alopecia areata, psoriasis, vitiligo, lichen planus, and more in dermatology. Contrary to the injectable biologics, these Janus kinase inhibitors can be taken per oral route and have greater patient acceptability. In this review, we seek to discuss the various indications of Janus Kinase inhibitors and their side effects. We also strive to discuss the monitoring for this class of drugs.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Society of Dermatologists, Venereologists and Leprologists of Nepal
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright on any research article is transferred in full to Nepal Journal of Dermatology, Venereology & Leprology upon publication. The copyright transfer includes the right to reproduce and distribute the article in any form of reproduction (printing, electronic media or any other form).